IN-VITRO TOLERABILITY OF HUMAN NASAL-MUCOSA - HISTOPATHOLOGICAL AND SCANNING ELECTRON-MICROSCOPIC EVALUATION OF NASAL FORMS CONTAINING SANDOSTATIN(R)

被引:10
作者
DEFRAISSINETTE, A
KOLOPP, M
SCHILLER, I
FRICKER, G
GAMMERT, C
POSPISCHIL, A
VONDERSCHER, J
RICHTER, F
机构
[1] INST VET PATHOL,ZURICH,SWITZERLAND
[2] ENT DEPT,LUZERN,SWITZERLAND
关键词
HUMAN; IN VITRO; NASAL MUCOSA; OCTREOTIDE; SANDOSTATIN(R);
D O I
10.1007/BF00757627
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
An in vitro human nasal model was developed as a tool to study the local tolerabiliity of nasal powder forms using excised nasal mucosa in a diffusion chamber. The suitability of this model was tested using Sandostatin(R) (SMS) an octapeptide analog of somatostatin, as a reference drug enhanced by Avicel(R) (microcrystalline cellulose) or lactose (100 mesh). The standard nasal spray vehicle was taken as a harmless control and 1% chenodeoxycholate (CDC) as a harmful control in terms of local tolerability. The extent of peptide permeation was determined by measuring SMS concentration in the receiving chamber. The labeling of SMS was detected by immunoperoxidase staining on cross sections. The local tolerability for all tested forms was assessed by histopathological examination and scanning electron microscopy. The apparent permeation coefficient allowed us to rank the absorption of the tested drug forms as Avicel > spray=lactose > 1%CDC. For all formulations, SMS was detected in the epithelium. No changes of the nasal mucosa could be observed with Avicel, lactose or nasal spray vehicle in the presence or absence of SMS. 1%CDC with or without drug showed an immediate destruction of the nasal epithelium. The validation of this in vitro model using human nasal mucosa will be further discussed as a tool for assessing the local tolerability of intranasally applied test substances.
引用
收藏
页码:295 / 301
页数:7
相关论文
共 18 条
[1]   LACK OF DELETERIOUS EFFECTS OF CORTICOSTEROID SPRAYS CONTAINING BENZALKONIUM CHLORIDE ON NASAL CILIATED EPITHELIUM - IN-VIVO RESULTS IN LABORATORY-ANIMALS [J].
AINGE, G ;
BOWLES, JAK ;
MCCORMICK, SG ;
RICHARDS, DH ;
SCALES, MDC .
DRUG INVESTIGATION, 1994, 8 (03) :127-133
[2]   THE USE OF CULTURED EPITHELIAL AND ENDOTHELIAL-CELLS FOR DRUG TRANSPORT AND METABOLISM STUDIES [J].
AUDUS, KL ;
BARTEL, RL ;
HIDALGO, IJ ;
BORCHARDT, RT .
PHARMACEUTICAL RESEARCH, 1990, 7 (05) :435-451
[3]   CHARACTERIZATION OF DEGRADABLE STARCH MICROSPHERES AS A NASAL DELIVERY SYSTEM FOR DRUGS [J].
BJORK, E ;
EDMAN, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 62 (2-3) :187-192
[4]   THE MOLECULAR-WEIGHT DEPENDENCE OF NASAL ABSORPTION - THE EFFECT OF ABSORPTION ENHANCERS [J].
DONOVAN, MD ;
FLYNN, GL ;
AMIDON, GL .
PHARMACEUTICAL RESEARCH, 1990, 7 (08) :808-815
[5]   ENTERAL ABSORPTION OF OCTREOTIDE - ABSORPTION ENHANCEMENT BY POLYOXYETHYLENE-24-CHOLESTEROL ETHER [J].
DREWE, J ;
FRICKER, G ;
VONDERSCHER, J ;
BEGLINGER, C .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 108 (02) :298-303
[6]   MICROSPHERES AS A NASAL DELIVERY SYSTEM FOR PEPTIDE DRUGS [J].
EDMAN, P ;
BJORK, E ;
RYDEN, L .
JOURNAL OF CONTROLLED RELEASE, 1992, 21 (1-3) :165-172
[7]   OCTREOTIDE TREATMENT OF ACROMEGALY - A RANDOMIZED, MULTICENTER STUDY [J].
EZZAT, S ;
SNYDER, PJ ;
YOUNG, WF ;
BOYAJY, LD ;
NEWMAN, C ;
KLIBANSKI, A ;
MOLITCH, ME ;
BOYD, AE ;
SHEELER, L ;
COOK, DM ;
MALARKEY, WB ;
JACKSON, I ;
VANCE, ML ;
THORNER, MO ;
BARKAN, A ;
FROHMAN, LA ;
MELMED, S .
ANNALS OF INTERNAL MEDICINE, 1992, 117 (09) :711-718
[8]   INTESTINAL-ABSORPTION OF THE OCTAPEPTIDE SMS-201-995 VISUALIZED BY FLUORESCENCE DERIVATIZATION [J].
FRICKER, G ;
BRUNS, C ;
MUNZER, J ;
BRINER, U ;
ALBERT, R ;
KISSEL, T ;
VONDERSCHER, J .
GASTROENTEROLOGY, 1991, 100 (06) :1544-1552
[9]   PRELIMINARY-RESULTS WITH SANDOSTATIN(R) NASAL POWDER IN ACROMEGALIC PATIENTS [J].
HARRIS, AG ;
WEEKE, J ;
CHRISTENSEN, SE ;
KAAL, A ;
ILLUM, P ;
ORSKOV, H .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (09) :72-75
[10]  
Holmberg K., 1994, Rhinology (Utrecht), V32, P74